following a full submission assessed under orphan equivalent process:
lanadelumab (Takhzyro®) is accepted for restricted use within NHSScotland.
Indication under review: For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
SMC restriction: patients with HAE type I or II, who would otherwise be considered for long-term prophylaxis treatment with C1-esterase inhibitor.
In a phase III study in patients with HAE, lanadelumab reduced the rate of angioedema attacks compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- lanadelumab (Takhzyro)
- SMC ID:
For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 December 2019